Cell death pathways as therapeutic targets in rhabdomyosarcoma

  • Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Simone FuldaORCiDGND
URN:urn:nbn:de:hebis:30:3-243092
DOI:https://doi.org/10.1155/2012/326210
ISSN:1369-1643
ISSN:1357-714X
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/22294874
Parent Title (English):Sarcoma
Publisher:Hindawi
Place of publication:London
Document Type:Article
Language:English
Year of Completion:2012
Year of first Publication:2012
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2012/05/23
Volume:2012
Issue:Article ID 326210
Page Number:5
HeBIS-PPN:303694092
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0